Study participants were 171 patients with available microbial sampling who were in clinical remission, to exclude a potential impact of disease activity. Patients with higher perceived stress had significantly lower alpha diversity, whereas patients with high vs low levels of anxiety and depressive symptoms showed no substantial differences in alpha diversity. In IBD patients with vs without depression or anxiety, beta diversity was significantly different (as shown in the Figure). Looking at specific operational taxonomic unit (OTUs), several significant alterations across groups were seen. These included significant increases in represents of Proteobacteria, such as Desulfovibrio (P=0.001), in ulcerative colitis patients, as well as decreases in numerous genus of Firmicutes, such as Lachnospiraceae (P<0.001), in Crohn’s disease and ulcerative colitis patients with depression; and decreases in Lactobacillales (Streptopcoccaceae) in Crohn’s disease patients with anxiety (P<0.001).
Figure: Beta diversity in IBD patients with vs without depression or anxiety [1]

Principal component analysis of microbial beta diversity according to severity (subgroup 1 = moderately increased, subgroup 2 = severe vs normal anxiety and depression) of psychological alteration (no ulcerative colitis patients with severe depression in this sample). CD, Crohn’s disease; UC, ulcerative colitis.
Dr Biedermann noted that further studies are warranted to gain more insight into the direction of the link between microbial composition and psychological wellbeing, and to investigate whether intestinal inflammation subsequent to microbial alterations or microbial metabolites itself may impair psychological wellbeing.
- Humbel F, et al. ECCO 2019, OP06.
Posted on
Previous Article
« Molecular effects of ustekinumab Next Article
Early remission of Crohn’s disease prevents progression »
« Molecular effects of ustekinumab Next Article
Early remission of Crohn’s disease prevents progression »
Table of Contents: ECCO 2019
Featured articles
Interview with Prof. Janneke van der Woude
New Compounds: Study Results
Short-term and Long-term Treatment Results
The right drug for the right patient
Vedolizumab superior to adalimumab in ulcerative colitis
Complementary and Alternative Medicine
Crohn’s disease exclusion diet + partial enteral nutrition in paediatric Crohn’s disease
Microbial composition and psychological wellbeing
Remission
Early remission of Crohn’s disease prevents progression
Proactive adalimumab trough measurements
Observational Studies
IBD risk of treatment with IL-17 antagonists
Basic and Preclinical Research
Immune cells and microbes: a happy marriage?
Genetics
Related Articles
May 9, 2019
Proactive adalimumab trough measurements
May 9, 2019
Immune cells and microbes: a happy marriage?
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com
